Large nontransplanted hepatocellular carcinoma in woodchucks: treatment with adenovirus-mediated delivery of interleukin 12/B7.1 genes.
BACKGROUND
Cytokine-based gene therapy strategies efficiently stimulate immune responses against many established transplanted tumors, leading to rejection of the tumor. In this study, we investigated the therapeutic potential of cancer immunotherapy in a clinically more relevant model, woodchucks with primary hepatocellular carcinomas induced by woodchuck hepatitis virus.


METHODS
Large (2-5 cm), established intrahepatic tumors were given an injection once with 1 x 10(9) plaque-forming units of AdIL-12/B7.1, an adenovirus vector carrying genes for murine interleukin 12 and B7.1, or of AdEGFP, the control virus, and regression of the tumors was then monitored. Five animals were used in total.


RESULTS
In four tumor-bearing animals, the antitumor response was assessed by autopsy and histologic analysis within 1-2 weeks after treatment. In all animals treated with AdIL-12/B7.1 therapy versus AdEGFP therapy, we observed substantial tumor regression (P =.006; two-sided unpaired Student's t test) accompanied by a massive infiltration of T lymphocytes. These tumors also contained increased levels of CD4(+) and CD8(+) T cells and interferon gamma (IFN gamma). In continuously growing tumor nodules given an injection of the control virus or in nontumoral liver, no such effects (i.e., tumor regression and increased levels of CD4(+) and CD8(+) T cells and IFN gamma) were detected. In the fifth animal, monitored for long-term antitumor efficacy by magnetic resonance imaging (MRI) after intratumoral vector administration by MRI guidance, the tumor was almost completely eliminated (> or = 95%) 7 weeks after treatment.


CONCLUSIONS
Adenovirus vector-based immunotherapy appears to be an effective treatment of large nontransplanted (orthotopic) tumors that acquire malignant characteristics in a stepwise process, reflecting the real-world scenario of hepatocellular carcinoma in humans.
Department of Molecular Biology [Cancer Research], University of Essen Medical School, Germany. brigitte.puetzer@uni-essen.de
B M
BM
Pützer
T
T
Stiewe
F
F
Rödicker
O
O
Schildgen
S
S
Rühm
O
O
Dirsch
M
M
Fiedler
U
U
Damen
B
B
Tennant
C
C
Scherer
F L
FL
Graham
M
M
Roggendorf
D000256:Adenoviridae; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology / Q000821:virology; D005822:Genetic Vectors; D006524:Hepatitis, Viral, Animal / Q000150:complications; D007167:Immunotherapy / Q000379:methods*; D007371:Interferon-gamma / Q000032:analysis; D018664:Interleukin-12 / Q000008:administration & dosage* / Q000235:genetics / Q000494:pharmacology*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology / Q000821:virology; D008392:Marmota
D000970:Antineoplastic Agents; D018664:Interleukin-12; D007371:Interferon-gamma